Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014; 15: 1503–12—In the eighth paragraph of the Results section of this Article, the first sentence should have been “Overall responses were noted in 59 (92%, 95% CI 83–97) of 64 patients (table 5)”. This correction has been made to the online version as of July 1, 2019.
[Corrections] Correction to Lancet Oncol 2014; 15: 1503–12
Leggi l'articolo originale